Compare FSTR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | PRQR |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.6M | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | FSTR | PRQR |
|---|---|---|
| Price | $28.96 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 29.6K | ★ 579.1K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $507,819,000.00 | $18,859,556.00 |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $65.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.16 | $1.07 |
| 52 Week High | $29.42 | $3.10 |
| Indicator | FSTR | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 49.78 |
| Support Level | $26.42 | $2.15 |
| Resistance Level | $29.42 | $2.49 |
| Average True Range (ATR) | 0.91 | 0.18 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 71.15 | 59.13 |
L.B. Foster Co is a U.S-based firm engaged in the manufacturing, fabrication, and distribution of products and services, especially for the rail, construction, energy, and utility industries. The company operates its business through two segments: Rail Technologies and Services and Infrastructure Solutions. Its principal business activity involves providing new and used rail, trackwork, and accessories, producing concrete railroad ties, insulated rail joints, power rail, track fasteners, cover boards, and sales of sells and rents steel sheet piling, H-bearing pile, and other piling products for foundation and earth retention requirements. It generates the majority of its revenues from the Rail Technologies and Services segment.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.